Takeda Pharmaceuticals is looking for patients to enroll in their new trial, described as;
“A Phase 2, Randomized, Controlled, Open-Label, Clinical Study of the Efficacy and Safety of Pevonedistat Plus Azacitidine Versus Single-Agent Azacitidine in Patients with Higher-Risk Myelodysplastic Syndromes (MDS),Chronic Myelomonocytic Leukemia (CMML), and Low-Blast Acute Myelogenous Leukemia (AML).”
Essentially, they want to evaluate how effective pevonedistat pus azacitidne is rather than azacitidine alone for people with the conditions listed above. The study needs about 117 people. After enrollment, everyone will be randomly assigned to one of the two different treatment groups for a treatment cycle of 28 days.
This multi-center trial will be conducted worldwide. Patients may qualify for this study if:
- 18 years of age or older
- Patients have intermediate, high, or very high-risk MDS based on the Revised International Prognostic Scoring System (IPSS-R), a standard prognostic tool, or have CMML
- Patients have low-blast AML defined as 20% to 30% myeloblasts in the bone marrow (low-blast AML), and ≤30% myeloblasts in the peripheral blood and considered appropriate for azacitidine based therapy
For more information visit www.clinicaltrials.gov (NCT02610777)
Contact: 1-877-674-3784; [email protected]
To learn more about MDS, check out the MDS Foundation here
